Wednesday, July 8, 2026

pharma · Molluscum Contagiosum · Common Warts (Verruca Vulgaris) · VRCA

Verrica Pharmaceuticals

Verrica Pharmaceuticals clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

West Chester, USA HQ
2013 Founded
80 Employees
Public company Type
VRCA · NYSE Ticker
Company details
Status
Public
HQ
West Chester, USA
Founded
2013
Employees
80
Programs
7
Drugs
3
Patents
7
Intelligence · Clinical Programs

Verrica Pharmaceuticals projects

3 ClinicalTrials.gov programs sponsored by Verrica Pharmaceuticals.

Verrica Pharmaceuticals has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Cantharidin

    Verrica Pharmaceuticals

    Common Warts (Verruca Vulgaris)

    phase 3 other active

    1 trial
  2. VP-102

    Verrica Pharmaceuticals

    Common Warts

    phase 3 other active

    1 trial
  3. VP-102-101

    Verrica Pharmaceuticals

    Molluscum Contagiosum

    phase 3 other completed

    2 trials

Frequently asked questions

How many clinical projects does Verrica Pharmaceuticals have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.